Report Library
All ReportsDatapack – Pharma R&D Annual Review 2016 Supplement: New Active Substances launched during 2015
December 02, 2016
Following on from our review of trends in the current pharmaceutical R&D pipeline, this supplement looks at the industry’s success stories of
2015 – the drugs that were launched to the market for the first time during the year. The white paper included with your purchase, Pharma
R&D Annual Review 2016 Supplement: New Active Substances launched during 2015, focuses exclusively on new active substances
(NASs): new chemical or biological entities where the active ingredient had received no prior approval for human use. As such, this list
represents a subset of all the first launches which Pharmaprojects reported during 2015, excluding the 68 new drug launches with reformulated
or non-NAS moieties, or biosimilars. This datapack covers the number of NASs launched by year, plus launches broken out by company,
therapeutic group, region, and more – allowing you to perform your own analysis and dive deeper into the underlying data.
Disease Group Covered: |
Allergy
Autoimmune/immunology Cardiovascular Dermatology Endocrine ENT/Dental Gastroenterology (Non Inflammatory Bowel Disease) Hematology Infectious Disease Metabolic Neurology Not Specified Obstetrics/Gynecology Oncology Ophthalmology Orthopedics Psychiatry Renal Respiratory Rheumatology (Non Autoimmune) Urology |